TITLE
2,6-disubstituted 4-amino-pyrimidines and 4-amino-triazines as treatments for processes driven by RhoJ/Cdc42 signaling, including melanoma, other cancers, retinal disorders, and cardiomyopathies.

INVENTORS
Marco DE VIVO, Anand GANESAN, Jose Antonio ORTEGA MARTINEZ, Sohail JAHID

DESCRIPTION
The present disclosure relates to novel 2-heterocycloalkyl-6-aryl-4-aminopyrimidine and 2-heterocycloalkyl-6-aryl-4-aminotriazine derivatives, collectively termed 2,6-disubstituted-4-amino-pyrimidines and 2,6-disubstituted-4-amino-triazines. The invention also relates to the use of said compounds, alone or in combination with other current anticancer drugs, in the treatment melanoma and/or growth of tumors in mammals. In particular, the here disclosed 2,6-disubstituted-4-amino-pyrimidines are potent inhibitors of RhoJ, and other members of the Cdc42 family, interaction with Pak1

APPLICATIONS
Drug-resistant cancers treatment, melanoma treatment, retinal disorders treatment, cardiomyopathies treatment

KEYWORDS
Anticancer drugs, Rho-J inhibition, 4-amino pyrimidine scaffold, 4-amino triazine scaffold

BIBLIOGRAPHIC DATA
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie

Application Number
IT102017000047189

Priority Date
May 02, 2017

Applicants
Fondazione Istituto Italiano di Tecnologia, The Regents of the University of California

CONTACTS
Technology Transfer Office
Angela Gagliolo
+39 010 71781 986
angela.gagliolo@iit.it